News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
